CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with ...
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...
Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...
GlobalData on MSN1d
BMS and 2seventy bio to discontinue enrolment in multiple myeloma trialDespite being open for over a year across 18 countries, the trial managed to recruit only 10% of its target population.
(Endpoints News) Bristol Myers Squibb and 2seventy bio announced discontinuation of enrollment in the phase III KarMMa-9 ...
US biotech 2seventy bio and partner Bristol Myers Squibb today revealed that they will discontinue enrollment in its ongoing ...
NEW YORK – Bristol Myers Squibb and 2seventy bio said on Wednesday they are discontinuing enrollment in the Phase III KarMMa-9 study evaluating maintenance treatment with CAR T-cel therapy Abecma ...
The biotech expects that stopping enrollment for KarMMa-9, a trial evaluating early use of the multiple myeloma cell therapy Abecma, should save it $80 million in the near term.
Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target remains the same with $37.00. Terence Flynn has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback